1994. The median rates of primary resistance to first-line drugs were INH (4.1%), streptomycin (STR) (3.5%), RIF (0.2%), and ethambutol (EMB) (0.1%). The median rates of acquired (secondary) resistance were much higher than those of primary resistance. Given the enhanced difficulty of treating drug-resistant strains, 12 the emergence and widespread dissemination of M. tuberculosis clones resistant to antimicrobial agents has adverse implications for TB control in the 21st century.
Substantial progress has been made in our understanding of the molecular basis of M. tuberculosis drug resistance in the last 3 years. 13 The goal of this review is to update the reader on recent progress in this critical area. Individuals interested in other topics pertaining to antimycobacterial agent research are referred elsewhere. [14] [15] [16] [17] [18] 
CHEMOTHERAPEUTICS AND DRUG RESISTANCE
The current short course M. tuberculosis drug treatment regimen uses an initial 2-month phase of daily therapy with INH, RIF, and pyrazinamide (PZA), plus either STR or EMB. 19, 20 This regimen is followed by daily therapy with INH and one other primary drug for the next 4 months. Drugs such as ethionamide (ETH), cycloserine, p-aminosalicylic acid, thioacetazone, kanamycin (KAN), capreomycin (CAP), viomycin (VIO), amikacin (AMI) and fluoroquinolones (FQs) are used as secondary or alternative agents to treat infections caused by strains resistant to commonly used medicines. Most expert panels and professional organizations, including the Centers for Disease Control and Prevention, the American Thoracic Society, and the World Health Organization recommend the use of directly observed therapy for patients with active TB. 21, 22 Successful chemotherapy results in conversion of sputum to a culture-negative state in 2 months and clearing of infiltrates on the chest radiograph between 4 and 6 months. 23, 24 Drug-resistant strains emerge when chemotherapy is intermittent or otherwise inadequate. 6, 25, 26 Several factors influence the degree of success of treatment programs including duration and complexity of therapy, ease of health care access, treatment cost, patient adherence, and drug side effects. In addition, some data suggest that certain HIV-positive patients may be at elevated risk of developing RIFresistant TB, perhaps due to drug absorption problems. [27] [28] [29] [30] [31] One of the assumptions associated with much of the research investigating drug resistance is that knowledge of the molecular genetic basis of this phenomenon will assist development of new chemotherapeutics by rational drug design strategies. It is also reasonable to think that rapid, sensitive, and unambiguous strategies for the detection of drug resistant strains may result. Both areas of research will benefit from the availability of a complete genome sequence from one M. tuberculosis strain. 32 
RIFAMPIN AND RELATED RIFAMYCINS
RIF is a semi-synthetic derivative of rifamycin that is used as a first-line TB medication. The highly effective bactericidal action of this drug against M. tuberculosis has made it a key component of therapy. 21, 22 The mechanism of RIF activity and resistance have been extensively studied in Escherichia coli. 33, 34 RIF binds to the β-subunit of ribonucleic acid (RNA) polymerase resulting in inhibition of transcription initiation. 33, 34 A similar mechanism of action has been demonstrated in M. smegmatis. 35 It was known for many years that missense mutations and short deletions in the central region of the RNA polymerase beta subunit gene (rpoB) result in RIF R E. coli. [36] [37] [38] [39] This insight led to characterization of the M. tuberculosis rpoB gene and to identification of a wide variety of mutations conferring RIF resistance. 13, 40, 41 Compilation of data available from many studies indicated that 315 of 329 (96%) of epidemiologically unrelated RIF R patient isolates of M. tuberculosis had 35 distinct point mutations, or short insertions and deletions located in an 81-bp core region (rifampin resistance determining region [RRDR] of rpoB codons 507-533 encoding 27 amino acids). 13, [41] [42] [43] [44] [45] [46] [47] Importantly, 43% of the strains had missense mutations in codon 531 (Ser) and 36% of organisms had codon 526 (His) alterations that would result in amino acid replacements. The most common amino acid substitutions were Ser531Leu (42%) and His526Tyr (23%). 13 The mechanism of resistance was not identified in 4% of RIF R clinical isolates because no mutations were detected in the 81-bp core region of rpoB nor elsewhere in the rpoB gene.
Several studies published from late 1995 to early 1998 have confirmed and extended the basic principles delineated by these findings. [48] [49] [50] [51] [52] [53] [54] [55] Caugant et al 48 analyzed the RRDR of rpoB in 66 M. tuberculosis patient isolates from Mozambique, including 41 RIF R isolates identified by the BACTEC radiorespiratory method. Most (39 of 41) RIF R strains had point mutations conferring amino acid replacements, and the frequency distribution of the affected codons was closely similar to that reported in earlier studies. Rinder et al. 49 determined the distribution of rpoB mutations in 49 RIF R isolates recovered in Germany and Sierra Leone. Resistance to RIF was determined by the proportion method. Similar to all other studies, mutations in codons 526 and 531 were the most common. Interestingly, the investigators reported differences in the frequency distribution of mutations in codon 516 and 526 in the isolates from the two geographic areas. However, inasmuch as the strains were not analyzed by IS6110 typing to determine epidemiologic independence, and there is no apparent reason to account for the reported geographic differences, it is possible that redundant sampling of clonally related isolates occurred.
Recently, Escalante et al. 50 conducted the first molecular genetic analysis of RIF R strains cultured from patients in Latin American countries. The investigators analyzed 19 epidemiologically-independent resistant strains from Peru and identified RRDR mutations in 18 organisms. Most strains had amino acid replacements at position 526 or 531.
PCR-SSCP and deoxyribonucleic acid (DNA) sequencing were used to analyze the core region of rpoB in 32 RIF R and 26 RIF S M. tuberculosis strains from Korea. 52 Susceptibility testing was done by the absolute concentration method. Most mutations occurred in codons 526 (37.8%) and 531 (24.4%). Two previously undescribed mutations in codons 507 and 518 were identified. In contrast to other studies, a high frequency of double mutations occurring in two separate codons (15.6%) and in a single codon (6.3% in codon 526; CAC->TGC, His-> Cys) was identified. Several groups have conducted studies with patient isolates designed to gain understanding of the relationship between RIF MICs and RpoB structural changes. [53] [54] [55] [56] This work is largely an extension of the investigations originally reported by Bodmer et al., 53 who found strong correlation of MICs for RIF and related rifamycins with certain RpoB variants. In particular, amino acid substitutions located at position 526 and 531 conferred high-level resistance to rifampin, rifabutin, and rifapentine. Ohno et al 54 analyzed the RRDR of RpoB in 40 clinical isolates of M. tuberculosis recovered in Japan. RIF susceptibility testing was done by the broth microdilution method and strains with MIC of ≥ 2 µg/ml were considered to be RIF R . All 13 strains with high level RIF resistance (MIC ≥ 64 µg/ml) had missense mutations in codons 516, 526, or 531. In contrast, all 21 susceptible organisms lacked changes at these positions. Of the six strains with MICs between 2 and 32 µg/ml, three strains had a missense mutation in either codon 516 or 526, and three strains lacked mutations in the RRDR.
The relationship between the degree of RIF resistance and RpoB missense changes was also analyzed by Taniguchi et al. 55 in 21 isolates of M. tuberculosis recovered from patients in Japan. RIF susceptibility testing was done by the proportion method or by broth dilution method. Twenty strains had amino acid alterations in the RRDR, and one strain had an Ala381Val substitution in the N-terminal region of RpoB. Isolates with mutations in codons 513 (5%), 526 (33%), and 531 (43%) had high level drug resistance (MIC ≥ 50 µg/ml). In contrast, amino acid substitutions located at position 514, 521, or 533 resulted in low-level resistance (MIC 12.5 µg/ml).
Similar findings were reported by Moghazeh et al., 56 who tested 24 RIF R clinical isolates of M. tuberculosis with known rpoB mutations against three rifamycin derivatives, RIF, rifapentine, and the related investigational drug KRM-1648 57, 58 to correlate levels of resistance with specific mutations. Susceptibility testing was done by the agar diffusion method. As recorded in other studies, [53] [54] [55] mutations in codons 513, 526, and 531 had high level resistance to RIF (MIC > 32 µg/ml), with the exception of strains with His526Leu or His526Asn substitutions, which had MICs of 8 and 16 µg/ml, respectively. In contrast to results reported by other investigators, 53-55 a Leu533Pro substitution was associated with an MIC > 32 µg/ml for RIF, rather than a low level MIC. The molecular explanation for this discrepancy is unknown. Importantly, all strains resistant to RIF were also cross resistant to rifapentine, and the same MIC values were identified. In contrast, KRM-1648 was able to overcome rifampin resistance in strains with four different genetic alterations. This finding suggested the theoretical possibility that KRM-1648 could be used to treat patients with certain types of rpoB mutations.
A recent analysis of M. tuberculosis strains constructed by molecular genetic strategies to contain defined rpoB mutant alleles on a plasmid has confirmed that mutations in the RRDR are responsible for resistance to this antimicrobial agent. 59 In addition, the study confirmed that KRM-1648 can overcome resistance to certain other rifamycins in vitro.
In summary, analysis of approximately 500 RIF R strains from global sources has found that 96% of RIF R clinical isolates of M. tuberculosis have mutations in the 81-bp core region of rpoB that alter the primary structure of RpoB (Fig. 1) . These mutations are absent in susceptible organisms. Although minor discrepancies have been reported, in general there is a strong correlation of specific amino acid substitutions and MIC. Missense mutations in codons 513, 526, or 531 result in high level RIF resistance, whereas amino acid changes at position 514 or 533 usually result in low level RIF resistance. Interestingly, Zhou & Jin 60 have recently shown that in E. coli, amino acid changes at positions 526, 531, 532, 533, and 563 destabilize initiation complexes at stringently controlled promoters. In essence, these RNA polymerase mutants behave like 'stringent' RNA polymerases in the absence of the stringent response in vivo. The molecular mechanism of resistance in 4% of the RIF R tuberculosis isolates that lack RRDR changes is unknown. Although a recent report demonstrated that ribosylative inactivation of rifampin by M. smegmatis is a principal contributor to low-level resistance to this antibiotic, there is no evidence that this process participates in M. tuberculosis drug resistance. 61 The wealth of data available from study of precisely defined and characterized resistant mutants recovered from humans with TB, and susceptibilities to four related rifamycins, will be of additional use if the crystal structure of the RpoB subunit is solved.
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ISONIAZID AND ETHIONAMIDE
INH is a synthetic, bactericidal agent that is used as a first-line drug against TB worldwide. Susceptible strains have an MIC of less than 0.05 µg/ml. Virtually all other mycobacteria and prokaryotes are INH resistant, and hence, this drug is used mainly to treat infections caused by M. tuberculosis complex members. Despite its widespread application in TB therapy and prophylaxis, and intensive laboratory investigation, there is much that is not yet understood about the bacterial targets and mode of action of INH.
katG and INH resistance
Decades ago, study of patient isolates of M. tuberculosis noted a correlation between INH resistance and loss of catalase-peroxidase activity. [62] [63] [64] [65] This observation eventually led to the cloning and sequencing of the structural gene (katG) for the enzyme. 66, 67 Molecular genetic studies confirmed that katG participated in mediating susceptibility to INH. 68 Moreover, katG was deleted from the chromosome of two strains with high level INH R isolates (MIC > 50 µg/ml). 66 However, many subsequent studies have shown that the vast majority of INH R strains contain the katG gene, a result indicating that deletion of this gene is very rare among patient isolates. [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] The observation that most INH R M. tuberculosis strains did not have gross deletions in katG stimulated a more precise analysis of the structure of katG in resistant isolates. Investigators on several continents have reported that many (~50-60%) INH R patient isolates have missense mutations, or small deletions or insertions that are not represented among INH S control strains. 13 Although a diverse array of distinct KatG changes are uniquely represented among INH R organisms, amino acid substitutions located at position 315Ser are the most abundant (Fig. 2) 50 on the basis of analysis of isolates from Peru. Statistically, the most common amino acid substitution is AGC (Ser)->ACC (Thr), but ACA (Thr), ATC (Ile), AGA (Arg), CGC (Arg), AAC (Asp), and GGC (Gly) changes also have been identified. R isolates. The codon numbering system described previously 38 was used. The figure summarizes mutations reported elsewhere. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] 129 Only changes occurring in strains with missense mutations at a single codon or organisms with single insertion-deletion events are included. One RIF R strain described previously 129 had a deletion of three nucleotides (CAT) that make up part of codons 514 and 515, resulting in Leu514 replacing Phe514-Met515. Mutant sequences with more than one point mutation or other combinations of mutations have been reported previously. 13 The codon numbers are designated on the basis of alignment of the translated E. coli rpoB sequence with the homologous part of the translated M. tuberculosis sequence and are not the positions of the actual M. tuberculosis rpoB codons. The figure is modified from one presented previously. 13 Three studies failed to identify amino acid substitutions in KatG 315Ser in high frequency. Pretorius et al. 77 did not find these changes in a sample of 39 strains recovered from South Africa, the USA, and Switzerland. However, this report was retracted soon thereafter when it was found that the PCR-SSCP strategy initially used to screen resistant strains failed to detect codon 315 polymorphisms present in 13 of 39 (33%) of the organisms. 78 Marttila et al. 79 83 studied the enzymatic properties of purified wild-type and the Ser315Thr mutant KatG proteins made in E. coli. Compared with the activities for wild-type KatG, the catalase activity of the Ser315Thr mutant was reduced 6-fold, whereas the peroxidase activity was only decreased < 2-fold. The mutant and wild-type proteins each had one heme group per subunit, a result indicating that the difference in enzymatic activity of the Ser315Thr mutant protein was not due to incomplete heme cofactor incorporation in the heterologous E. coli host. The wild-type KatG was more efficient than the mutant enzyme in ability to convert INH (prodrug) to isonicotinic acid (activated INH). Taken together, the results are consistent with the idea that the Ser315Thr mutant is a competent catalase-peroxidase that has reduced ability to metabolize INH. Hence, amino acid substitutions at position 315 appear to strike a balance between the need to maintain active catalase-peroxidase activity to detoxify host antibacterial radicals, and reduce conversion of prodrug to active INH, a process that would normally kill the bacterium.
The most commonly occuring polymorphism found in the katG gene is a CGG<->CTG change resulting in Arg<->Leu variation at amino acid position 463. 13, 72, 84, 85 An initial analysis suggested that the KatG463 Leu substitution was causally involved in INH resistance. 72 However, a subsequent study demonstrated that most isolates with this amino acid had other KatG structural changes, a result suggesting that the KatG463Leu variant was merely a convenient surrogate marker for INH R organisms. 74 Several studies suggest that this is the case. Strains with Arg463Leu substitutions have essentially wild-type levels of catalase-peroxidase activity. 72, 86 Site-directed mutagenesis demonstrated that the presence of Leu at codon 463 (rather than Arg) did not alter catalaseperoxidase activity. 87 The Arg463Leu substitution is present in many INH S strains, especially organisms recovered in China, the former Soviet Union, and certain other areas of Asia. 84, 85, 88 Detailed kinetic and spectroscopic studies failed to identify differences in the properties of KatG463Arg and KatG463Leu proteins, moreover, no significant difference in catalase or peroxidase activity, or other enzymatic parameters between the two purified proteins has been found in vitro. 86 For example, both proteins oxidize INH to isonicotinic acid, and display the same dependence on INH concentration.
However, data derived from study of isogenic strains of bacille Calmette-Guérin (BCG) constructed to express either KatG463Arg or 463Leu were noteworthy because they suggested that subtle differences may exist between the two proteins. 87 Most notably, the MIC of BCG transformed with the 463Leu variant was slightly higher than BCG expressing the 463Arg protein (1.0 µg/ml vs 0.5 µg/ml). This result is consistent with the observation that Mycobacterium bovis strains, all of which naturally have KatG463Leu, 74, 89 are slightly less susceptible to INH than most M. tuberculosis strict sense organisms. In addition, of the 14 low-level INH-resistant catalase-positive organisms reported by Rouse et al., 87 nine had Leu at KatG codon 463, and none of these organisms had other mutations in katG or the inhA region.
Rouse et al. 87 used site-directed mutagenesis to alter the wild-type katG gene from M. tuberculosis at 13 codons previously shown to be mutated in INH R clinical isolates. The effects on drug susceptibility of the resulting amino acid changes were determined with complementation assays in katG-defective, INH R strains of M. smegmatis and M. bovis BCG. Importantly, nine of the 13 variant amino acids were shown to confer INH resistance, including Arg104Leu, His108Gln, Asn138Ser, Leu148Arg, His270Gln, Thr275Pro, Ser315Thr, Trp321Gly, and Asp381Gly. These results were consistent with modelling studies suggesting that residues 104 and 108 are located at or near the enzyme catalytic site, and residues 270, 275, and 315 participate in heme binding. 90, 91 inhA locus and INH resistance ETH is a structural analog of INH that is used as a second-line drug against TB. ETH is thought to inhibit mycolic acid biosynthesis in M. tuberculosis. 92, 93 Several studies have shown that for certain strains, low level INH resistance is correlated with co-acquisition of ETH resistance, suggesting that INH and ETH share a molecular target. [94] [95] [96] Molecular genetic study of single-step spontaneous INH-ETH resistant mutants of M. smegmatis and M. bovis identified a two-gene operon with contiguous open reading frames designated mabA and inhA, coding for products that participated in resistance to both INH and ETH 95 ( Fig. 3 ). The predicted protein product of mabA had greatest identity with 3-ketoacyl-acyl carrier protein (ACP) reductase coded for by fabG of E. coli, an enzyme involved in fatty acid biosynthesis. 96 The mycobacterial inhA-encoded enoyl reductase had 40% amino acid sequence identity with E. coli envM-encoded enoyl reductase. InhA from M. tuberculosis has been purified, crystallized, and shown to be an NADH-dependent enoyl-ACP (acyl carrier protein) reductase with specificity for long-chain enoyl thioester substrates. [96] [97] [98] The sum of the evidence suggests that MabA and InhA participate in mycolic acid biosynthesis.
The identification of a Ser94Ala substitution in InhA conferring resistance to INH and ETH in the laboratory led to the hypothesis that missense mutations in inhA would occur in resistant M. tuberculosis strains recovered from patients. DNA sequence analysis of the inhA locus in 46, 74 Interestingly, the Ser94Ala amino acid replacement was not found in the patient isolates. However, 15 isolates had mutations in the upstream putative regulatory region of the inhA locus. Study of INH R clinical isolates from the Netherlands showed that 11 of 51 strains had a C->T substitution flanking the 5′ side of the presumed ribosome binding site upstream of mabA. 74 These strains lacked katG codon 315 mutations.
On the basis of identification of mutations in the upstream region of inhA locus, it was hypothesized that these changes result in increased InhA protein expression, thereby elevating the drug target levels and producing INH resistance via a titration mechanism. To test this hypothesis, a multicopy plasmid containing the inhA gene was transformed into M. smegmatis and M. tuberculosis strains. 99 High-level INH resistance was conferred only to M. smegmatis. The promoter region containing mutations at positions thought to be located at -8 and -15 upstream from translational start site of mabA were cloned into an integrating, single copy vector and then transformed into M. smegmatis and M. tuberculosis. 99 The (Table 1) . These results were similar to the previous observation that the Ser94Ala substitution produced a five-fold increase in K m for NADH binding. 96 Furthermore, all mutant enzymes had an increased K d for NADH. On the basis of crystal structure analysis, all amino acid substitutions would be located in the NADH binding site (Fig. 4) . Taken together, the data are consistent with the idea that INH resistance in these strains is related to the reduced NADH binding affinity for enoyl reductase. 101 Several recent papers have described the detailed in vitro chemical interactions between INH and mycobacterial proteins. [102] [103] [104] [105] [106] [107] INH activated by catalase-peroxidase binds exclusively to enoyl-reductase-NADH complex in the presence of manganese and oxygen. 104, 106 The three dimensional structure for the ternary complex of wildtype enoyl reductase of M. tuberculosis with NADH and activated INH has been determined. 107 The acylpyridine fragment of INH is found to be covalently attached to the C4 position of NADH. It is believed that a similar adduct between the electrophilic, activated species of INH produced by KatG and the enzyme-NADH complex would form a ternary complex in vivo, resulting in the inactivation of enoyl reductase followed by inhibition of mycolic acid biosynthesis.
In Automated DNA sequence analysis discovered that four amino acid-altering mutations were present in kasA in recent INH-resistant patient isolates (Fig. 5) . Susceptible strains lacked mutations in this gene. Importantly, two of the resistant isolates lacked mutations in katG and the inhA locus. The crystal structure of the E. coli homologue of KasA has recently been reported. 109 Three of the four M. tuberculosis KasA amino acid changes mapped to the active site of the E. coli molecule. The fourth amino acid substitution was located at the carboxyterminus of KasA and may alter protein-protein interactions. Taken together, the data suggest that KasA is a new INH target useful for the development of new therapeutics and the identification of drug-resistant strains.
oxyR, ahpC, and INH resistance
In E. coli and Salmonella typhimurium, katG is part of an oxidative stress regulon induced by oxyR in response to the detrimental effects of H 2 O 2 . [110] [111] [112] The oxyR gene controls expression of katG and several other genes including ahpC, encoding the small subunit of alkylhydroperoxide reductase. 113, 114 Mutations in either oxyR or ahpC in E. coli confer INH susceptibility to this otherwise INH-insensitive bacterium. 115 To determine if mutations in oxyR or ahpC participate in INH resistance in M. tuberculosis, these genes were recovered from a genomic library made from strain H37Rv. 116, 117 oxyR and ahpC were discovered to be tightly linked and divergently transcribed, [116] [117] [118] [119] attributes typical of the LysR family of transcriptional regulators in enteric organisms.
120 Surprisingly, the oxyR gene was naturally inactivated by accumulation of multiple genetic lesions including several frameshift mutations, point mutations, and deletions. 116, 117 These alterations were also present in other members of the M. tuberculosis complex; however, an intact oxyR gene was located 109 bp upstream of ahpC in Mycobacterium leprae. Transformation of the oxyRahpC region of M. leprae into M. tuberculosis resulted in strain H37Rv acquiring resistance to 5 µg/ml of INH. These results were interpreted to mean that the natural oxyR lesions found in M. tuberculosis are at least partially responsible for the exquisite sensitivity of M. tuberculosis to INH. 116, 117, [121] [122] [123] A corollary of the hypothesis that susceptibility of M. tuberculosis to INH is in part due to loss of OxyR function is that mutations that result in enhanced expression of other genes whose products are involved in the INH pathway might compensate for the loss of oxyR. Consistent with this idea, mutations in the ahpC promoter sequences were identified in a small number of INH R organisms deficient in KatG activity, but were not present in INH S bacteria. 124 Reporter gene constructs using lacZ combined with western immunoblot analysis showed that several of the ahpC mutant alleles had enhanced transcriptional activity. Transformation of a multicopy plasmid containing the wild-type ahpC gene into M. tuberculosis H37Rv resulted in increased resistance to cumene hydroperoxide, an observation suggesting that increased AhpC activity could compensate for the loss of KatG activity in the detoxification of organic peroxides 124 (Fig. 6) . Hence, the weight of the genetic and biochemical evidence indicated that the ahpC mutations represented compensatory alterations occuring as a consequence of loss of catalaseperoxidase activity. These observations raised the possibility that upregulation of AhpC expression may participate in INH resistance in M. tuberculosis strains lacking mutations in katG or inhA locus.
Because all studies cited above used laboratory generated INH R strains or very few clinical isolates, it was important to determine the frequency with which oxyRahpC mutations were present in a large group of epidemiologically independent human TB isolates. Sequence analysis of 229 M. tuberculosis isolates from intercontinental sources characterized previously for polymorphisms in katG and the inhA locus was conducted. 125 The entire 1221-bp region was studied in 118 isolates, and 111 other isolates were sequenced for oxyR, ahpC, or the 105-bp oxyR-ahpC intergenic region. Only nine mutations were identified in the 105 bp oxyR-ahpC intergenic region of INH R strains, indicating that these mutations were relatively rare among a broad spectrum of INH R strains. Importantly, most INH R strains with katG codon 315 sub- The data are a compilation of mutations described previously. 121, [124] [125] [126] 128, 240 Numbering is based on nucleotide position relative to the mRNA start site. 119 stitutions that significantly decrease catalase activity and confer high-level MICs for INH, lacked alterations in ahpC or oxyR-ahpC intergenic region. The relative paucity of ahpC compensatory mutations was attributed to rare occurrence of a KatG null phenotype among epidemiologically independent INH R strains. Taken together, the data are consistent with the hypothesis that some polymorphisms located in the oxyR-ahpC intergenic region are selected due to reduction in catalase or peroxidase activity attributable to katG changes arising with INH therapy. The analysis also found two mutations at codons 73 (GAC->CAC, Asp->His) and 191 (CTC->CGC, Leu->Arg) in INH R isolates, although the exact relationship of these amino acid changes to INH resistance is unknown. There was no preferential association of polymorphisms in oxyR with INH R organisms, the expected result given that oxyR is a pseudogene. 116, 117 An interesting offshoot of the analysis of ahpC-oxyR polymorphism was the identification of a point mutation in oxyR that specifically differentiates M. bovis from other members of the M. tuberculosis complex. 126 Essentially identical results were recently reported on the basis of analysis of 57 INH-resistant clinical strains of M. tuberculosis from patients in Korea, Brazil, Mexico, China, and the USA. 127 All strains had a wild-type inhA gene as assessed by PCR-SSCP. No ahpC promoter or structural mutations were identified in 25 catalasepositive, isoniazid-resistant isolates, or 25 INH S organisms. Eight catalase-negative strains highly resistant to INH (MICs ranging from 10 to 125 µg/ml) had alterations in both katG and ahpC regulatory sequences. Three strains had katG deletions, one strain had a nonsense mutation, one strain had a single base pair insertion, and three strains had missense mutations. The promoter mutations were located at -6, -9, -10, -12, -30, and -42 relative to the transcriptional start site; with the exception of the -42 change (T->C), AhpC overproduction was documented by immunoblot analysis. The commonly occurring KatG Ser315Thr substitution was not associated with ahpC upstream mutations, a result that confirmed previous findings. 125 In an attempt to determine the frequency distribution of mutations in targeted areas of katG, inhA, and ahpC among INH R strains, Telenti et al. 128 analyzed 95 M. tuberculosis isolates from Spain by PCR-SSCP. Susceptibility testing was done by the proportional method. The mutation frequencies were as follows for INH R strains -katG (36.8%), inhA (31.6%), katG-inhA (2.6%), ahpC (13.2%) and katG-ahpC (2.6%). All five distinct mutations detected in the ahpC promoter region had been previously reported by other investigators. Interestingly, the frequency of inhA regulatory region mutations was considerably higher than reported by other investigators. Although the exact reason is unclear, we note that strains were classified as a distinct genotype on the basis of a rep-PCR method that, unlike the IS6110 profiling strategy, has not yet been validated in large studies. Hence, there is a formal possibility that some redundant sampling of epidemiologically related strains was a factor.
Notwithstanding a report 125 In summary, mutations in a relatively large number of genes have been associated with isoniazid resistance. Evidence implicates mutations in katG, inhA, and kasA as causally involved in mediating resistance to this critical drug. oxyR in M. tuberculosis is a pseudogene. Mutations in the promoter region of ahpC occur in many or most catalase-negative, INH R isolates. These mutations appear to be compensatory and are presumably selected after reduction in catalase-peroxidase activity attributable to katG changes arising with INH therapy. However, this sequence of events has not yet been documented to occur in humans. AhpC itself does not appear to directly mediate INH resistance. The mechanism of INH resistance in some strains remains to be determined.
STREPTOMYCIN
STR is an aminocyclitol glycoside antibiotic that is one of the first line drugs used to treat TB. In E. coli STR binds to 16S rRNA, inhibits translational initiation, and detrimentally affects translation fidelity. 131, 132 Mutations associated with STR resistance in M. tuberculosis have been identified in the 16S rRNA gene (rrs) and rpsL gene encoding ribosomal protein S12. [133] [134] [135] [136] [137] [138] [139] [140] In contrast to other bacteria which have multiple copies of rRNA genes, M. tuberculosis complex members have only one copy. 141, 142 Hence, single nucleotide changes can potentially produce antibiotic resistance. Point mutations in rrs are clustered in two regions around nucleotides 530 and 915. The 530 loop of 16S rRNA is highly conserved and is located adjacent to the 915 region in secondary structure models. Several nucleotides in both regions interact with the ribosomal S12 protein. 143 In the 530 loop, C->T transitions are observed at positions 491, 512, and 516, and transversions (A -> C or T) have been reported at position 513. In the 915 region, C->A or G alterations at position 903 and A->G changes at position 904 are common. These observations are consistent with footprinting experiments done in E. coli that show STR interacts directly with the nucleotide sites in the 530 loop and 915 regions of 16S rRNA and that mutations at these sites result in STR R E. coli.
131,132
The majority of point mutations producing STR resistance occur in rpsL. The most common mutation is an AAG->AGG change in codon 43 resulting in a Lys->Arg substitution; less frequently, an AAG->ACG (Lys->Thr) substitution is observed. 13, [134] [135] [136] [137] [138] [139] [140] Mutations also occur in codon 88, and these result in Lys->Arg (AAG->AGG) or Lys->Gln (AAG->CAG) amino acid replacements. The analogous mutations have been recorded in STR R strains in several bacterial species, presumably because the S12 protein is highly conserved.
Sreevatsan et al. 138 determined the frequency distribution of rpsL and rrs mutations in 78 STR R and 61 STR S isolates recovered from patients worldwide. rrs mutations were found in the 915 or 530 loop regions in 8% of the resistant isolates. Three previously undescribed mutations were identified in the 915 region of rrs, an area encoding a STR binding site in 16S rRNA. The nucleotide positions were 798 (C->T), 877 (G->A), and 906 (A->C). In addition, 54% of the STR R isolates had missense mutations in codons 43 To gain insight into the relationship of RpsL and rrs changes and STR MIC levels, Cooksey et al. 139 analyzed 45 STR R isolates for phenotypic resistance and mutations. Antimicrobial susceptibility testing was performed by the agar proportion method. Twenty-four isolates had high level resistance (MIC >500 µg/ml) and 20 isolates had low level resistance (MIC, 10 µg/ml). All 24 high level resistance mutants had a Lys43Arg change in RpsL. Of the low level STR R mutants, only one isolate had a C->G change at position 903 in the 915 region of rrs gene. No mutations were detected in the 530 loop of the rrs gene, indicating the existence of alternative mechanisms for 19 of 45 (42%) low level STR R isolates. The investigators suggested that cell permeability changes, production of aminoglycoside-modifying enzymes, or alterations in other ribosomal molecules may contribute to low level drug resistance in M. tuberculosis strains lacking rpsL and rrs changes.
Meier et al. 140 also studied the association of particular RpsL amino acid replacements and rrs mutations with STR MIC level. MIC was determined by agar diffusion method and resistance was defined as MIC of >2 µg/ml. Of the 19 STR R isolates, four had Lys43Arg substitutions and another four isolates had Lys88Arg changes in RpsL. Six isolates had changes in the 530 loop region of 16S rRNA and the remaining five (26%) isolates had wild-type rpsL and rrs genes. Amino acid changes in RpsL correlated with high level resistance (MIC > 500 µg/ml) and mutations in rrs correlated with intermediate level of resistance (MIC < 250 µg/ml). Low level resistance (MIC < 50 µg/ml) was also identified in strains that lacked mutations in the regions of rpsL and rrs studied. Interestingly, the susceptibilities of STR R and STR S isolates were investigated in the presence or absence of Tween, a membrane-active agent capable of reducing membrane barriers. The MICs for STR S and mutants with high and intermediate levels of resistance were not affected when Tween was included. However, the MICs of low level STR R mutants decreased significantly by approximately 10 fold suggesting a permeability barrier may contribute to resistance.
In summary, about 65-75% of STR R isolates have resistance-associated changes in RpsL or rrs. Failure to identify resistance-associated variation in these genes in 25-35% of organisms indicates that other molecular mechanisms of STR resistance exist. The hypothesis that low level resistance is associated with permeability barrier requires further evaluation. Although resistance to aminoglycoside antibiotics in some bacteria is due to drug inactivation via acetylation, 144 this mechanism has not been described in M. tuberculosis.
PYRAZINAMIDE
PZA is a structural analog of nicotinamide that is used as a first-line TB drug. 145, 146 PZA kills semi-dormant tubercle bacilli under acidic conditions. 147, 148 It is hypothesized that in the acidic environment of phagolysosomes, the tubercle bacilli produce pyrazinamidase, an enzyme which converts PZA to pyrazinoic acid, the active derivative. 149 Consistent with this hypothesis, PZA R M. tuberculosis isolates lose pyrazinamidase activity. 150, 151 To define the molecular mechanism of PZA resistance, Scorpio et al. 152 cloned and characterized the M. tuber- 152 All four strains lacked pyrazinamidase activity and had MICs > 500 µg/ml. In contrast, susceptible organisms had the identical wild type sequence. Transformation of the wild type pncA gene into a PZA R mutant derived from H37Rv restored pyrazinamidase activity and PZA susceptibility. The results provided strong molecular genetic and biochemical evidence that pncA mutations conferred PZA resistance.
To gain additional insight into the role of pncA mutations in PZA resistance, Sreevatsan et al. 154 sequenced this gene in 67 PZA R and 51 PZA S M. tuberculosis clinical isolates from diverse geographical localities, and with a wide diversity of IS6110 subtype. PZA susceptibility testing was done by BACTEC or the proportion method. All PZA S isolates had the identical pncA allele, whereas 72% of PZA R isolates had pncA mutations. A total of 17 previously undescribed mutations, including missense changes, upstream presumed regulatory mutations, nucleotide insertions and deletions, and termination mutations were found (Fig. 7) . Interestingly, approximately 40% of the distinct amino acid substitutions involved replacement with a proline residue. Although the significance of this observation is not clear, we note that if these changes occurred in alpha-helical regions, protein structure might be altered, thereby detrimentally affecting pyrazinamidase activity. Lack of pncA mutations in 19 of 67 (28%) PZA R isolates suggested the existence of at least one additional gene participating in PZA resistance.
Similar results were reported by Scorpio et al. 155 who sequenced pncA in 34 PZA R clinical isolates and found that 33 of the organisms had 26 distinct mutations, most of which were previously undescribed. Nucleotide substitutions, insertions, and deletions were identified, and these sequence alterations were dispersed throughout the pncA gene. In addition, in vitro generated resistant mutants lost pyrazinamidase activity, and had high level drug resistance (MIC > 900 µg/ml). Sequence analysis of 14 laboratory generated resistant strains identified nucleotide substitutions, insertions, and deletions in eight organisms, results indicating that many of these mutants had the same mechanism of resistance as PZA R clinical isolates. Recently, Hirano et al. 156 reported that 32 of 33 PZA R strains cultured from patients in nine countries had pncA mutations, whereas PZA S strains lacked changes in this gene.
Hence, a remarkably wide array of pncA mutations resulting in structural changes in PncA have been identified in greater than 70% of drug resistant clinical isolates. It is presumed that these structural changes detrimentally change enzyme function, thereby altering conversion of PZA to its bioactive form. One hypothesis to account for the extreme diversity in resistance-associated mutations is that because the enzyme consists of only 186 amino acids, any amino acid substitution may be likely to detrimentally alter function. Susceptible organisms lack pncA changes. The details of the molecular mechanism of PZA-pyrazinamidase interaction, and pyrazinoic acid formation are unknown. Studies designed to delineate pyrazinamidase structure-function relationships are clearly needed to assist understanding of the mechanism of action of PZA, and resistance to this drug.
ETHAMBUTOL EMB ([S,S']-2,2'-[ethylenediimino]
)di-1-butanol is a bactericidal first-line drug used to treat TB. Early studies reported that EMB inhibited incorporation of mycolic acids into the cell wall.
157,158 Takayama & Kilburn 158 showed that EMB inhibited the transfer of arabinogalactan into the cell wall of M. smegmatis, a process that led to the accumulation of mycolic acids and their cognate trehalose esters. The identification of β-D-arabinofuranosyl-1-monophosphodecaprenol as the major intermediate in the biosynthesis of arabinogalactan, and the rapid accumulation of this intermediate following EMB administration suggested that the EMB target was an arabinosyl transferase. 159 Only the dextro isomer of EMB is biologically active, an observation consistent with the idea that the drug binds to a specific cellular target. 160 Inasmuch as EMB has been proposed to be an arabinose analog, the specific target is likely to be an arabinosyl transferase, presumably a functionally-important site.
To gain insight into the molecular genetics of arabinan biosynthesis, Belanger et al. 161 identified a two gene locus (embAB) in Mycobacterium avium that encodes arabinosyl transferases mediating polymerization of arabinose into arabinogalactan. Working in parallel, Telenti et al. 162 cloned and sequenced genes encoding the putative EMB target in M. smegmatis. Three genes organized as an operon were identified and designated embCAB. The corresponding M. tuberculosis embCAB genes were then identified from an ordered cosmid library. Sequence analysis and genetic studies revealed that the three genes were organized as a 10 kbp operon. A collection of 72 strains of M. tuberculosis including 28 EMB R isolates was examined for mutations in the embCAB operon by automated DNA sequencing and SSCP analysis. Among epidemiologically unrelated EMB R isolates, 13 of 28 (47%) had mutations in codon 306 of embB that would produce Met->Ile or Met->Val substitutions (Fig. 8) isolates from diverse geographical localities, and representing 70 distinct IS6110 fingerprints, discovered that 69% of EMB R isolates had an amino acid substitution in EmbB that was not found in EMB S strains. The great majority (89%) of strains had a missense mutation in codon 306; moreover, missense mutations were also identified in three additional codons: Phe285Leu, Phe330Val, and Thr630Ile. These mutations were also uniquely represented among EMB R organisms. For strains with the Met306Leu, Met306Val, Phe330Val, and Thr630Ile replacements, EMB MICs were generally higher (≥ 40 µg/ml) than those for organisms with Met306Ile substitutions (20 µg/ml). The data are consistent with the idea that specific amino acid substitutions in EmbB detrimentally affect the interaction between EMB, a putative arabinose analog, and EmbB, likely to be an arabinosyltransferase. Taken together, many of the amino acid substitutions in EmbB undoubtedly mediate EMB resistance, rather than act simply as surrogate markers for drug-resistant organisms.
To address the potential significance of embB mutations and EMB resistance in non-tuberculous mycobacteria, Alcaide et al. 164 characterized the embB ERDR region in a panel of strains representing 13 species. High level natural resistance to EMB (MIC ≥ 64 µg/ml) was associated with a variant amino acid motif in the ERDR of M. abscessus, M. chelonae, and M. leprae. Transfer of the M. abscessus embB allele to M. smegmatis resulted in a 500-fold increase in MIC, a result supporting the notion that ERDR determines intrinsic and acquired resistance to EMB in some species. This result has been confirmed by Lety et al. 165 in studies with M. smegmatis. To summarize, embB mutations are associated with EMB resistance in roughly 70% of EMB R isolates of M.
Tuberculosis drug resistance update 15 tuberculosis. 162, 163 It is likely that the molecular basis of EMB resistance involves altered interaction of the drug with one or more products of the EmbCAB operon. The cause of EMB resistance in many organisms lacking mutations in the ERDR of EmbB is unknown. It is reasonable to anticipate that the identification of additional altered EmbB variants will contribute to a fuller understanding of structure-function relationships in this putative arabinosyltransferase.
FLUOROQUINOLONES
Ciprofloxacin (CIP) and ofloxacin (OFX) are synthetic derivatives of nalidixic acid that are currently used as second-line or alternative TB drugs. 166, 167 These FQ drugs are bactericidal against M. tuberculosis. Their target is DNA gyrase, an ATP-dependent type II DNA topoisomerase that catalyzes negative supercoiling of DNA. [168] [169] [170] DNA gyrase is a heterotetramer composed of two A and two B subunits, encoded by the gyrA and gyrB genes, respectively. 169 FQs bind to gyrase and inhibit supercoiling, thereby disrupting cellular processes dependent on DNA topology. As with other drugs, FQ resistance develops rapidly when used alone against M. tuberculosis, or when added as a single drug to a failing therapy. [171] [172] [173] [174] [175] Cross-resistance among FQs is common. 176 Clinical isolates of M. tuberculosis with acquired resistance to FQs are usually resistant to RIF and one or more other first-line drugs because FQs are frequently used to treat MDR-TB. 172 Cloning and sequencing of the gyrA and gyrB genes from M. tuberculosis resulted in the mapping of mutations that are associated with FQ resistance in many strains. [173] [174] [175] 177 Mutations associated with high level FQ resistance are clustered in a short region of 40 amino acids in GyrA referred to as the quinolone resistance determining region (QRDR). 168 Sequence analysis of the QRDR of gyrA in 39 CIP S and 15 CIP R patient isolates of M. tuberculosis identified polymorphisms in codons 90, 91, 94, and 95. 177 Missense mutations in codons 90, 91, and 94 were associated with CIP R (MIC ≥ 4 µg/ml) whereas CIP S strains lacked mutations in these three codons. There was no simple relationship between a codon 95 polymorphism (AGC, Ser or ACC, Thr) and CIP susceptibility. That is, this polymorphism appears to be naturally-occuring variation that has no known functional participation in FQ resistance. A missense mutation (GAC->CAC, Asp->His) in codon 89 has been associated with ofloxacin resistance in M. smegmatis, but, has not been reported for CIP R M. tuberculosis.
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Analysis of strains recovered from 22 patients infected with FQ-resistant MDR-TB in New York City found that many distinct amino acid substitutions were uniquely associated with resistant strains. 174 Automated DNA sequencing of the QRDR of gyrA identified mutations that would result in amino acid changes in codon 90 (Ala->Val), or codon 94 (Asp->Ala, Asn, Gly, His, or Tyr). Isolates from four patients lacked mutations in this region of gyrA, indicating that changes elsewhere in gyrA or in other genes were responsible for the resistance phenotype.
To test whether specific GyrA amino acid substitutions were associated with distinct levels of FQ resistance, 13 CIP R patient isolates were examined for CIP susceptibility relative to control organisms with the same IS6110 DNA fingerprint. 179 Quantitative estimates of FQ susceptibility were made by determining the antibiotic concentration required to inhibit growth in liquid culture by 50% (ID 50 ). Measurement of ID 50 provided the same information as the MIC 50 , but ID 50 determination was logistically simpler and less expensive. The study found that specific gyrA alleles were associated with distinct levels of drug susceptibility for 11 isolates with nucleotide changes that alter the amino acid sequence of the GyrA QRDR. For example, amino acid replacements in residue 90 (Ala->Val) resulted in a 16-fold relative increase in resistance, position 94 changes (Asp->Asn, His, or Tyr) produced a 30-fold relative increase in MIC, and a Asp94Gly replacement resulted in a 60-fold relative increase in MIC.
FQ resistance in other bacteria can involve decreased cell wall permeability to the drug or active drug efflux. 168 However, although some investigation has occurred in M. smegmatis, 180 there is no firm evidence that mutations altering an active efflux pump contribute to FQ resistance in M. tuberculosis isolates recovered from patients. Due to the difficulties in treating MDR-TB, newer or modified versions of existing drugs have been tested for their potential use in anti-TB therapy. Lounis et al. 181 compared the activity of ofloxacin, levofloxacin, and sparfloxacin in a murine TB model. Sparfloxacin was far more bactericidal than other FQs. Sparfloxacin sensitive organisms had an MIC of 0.15 µg/ml and no single step resistant mutants were selected at concentrations of 2.5 µg/ml. Two step-wise gyrase mutations were required to achieve high level resistance (MIC ≥ 5 µg/ml) to sparfloxacin. These data are consistent with a report that sparfloxacin was four times as effective as CIP against resistant mutants in vitro.
In summary, acquired resistance to FQs in 42-85% of clinical isolates of M. tuberculosis has been shown to be associated with gyrA mutations in the QRDR region. Other potential resistance mechanisms include mutations elsewhere in gyrA, or in gyrB, decreased drug permeability, and active drug efflux.
KANAMYCIN, AMIKACIN, VIOMYCIN AND CAPREOMYCIN
KAN and AMI are aminoglycoside antibiotics that inhibit protein synthesis by inhibiting the normal function of ribosomes. 182, 183 VIO and CAP are basic peptide antimicrobial agents that also inhibit protein synthesis. 184, 185 These drugs are used as second-line anti-TB agents. Resistance to KAN, AMI, VIO, and CAP is relatively uncommon in clinical isolates, presumably because these drugs are used relatively rarely to treat TB. As is the case for FQs, most organisms resistant to these drugs are also resistant to several first-line agents. A report that only 1% of 466 isolates from New York City were resistant to KAN or CAP illustrates the rarity of resistance to these drugs. 6 Crossresistance between KAN and VIO and between KAN and CAP is variable among laboratory generated resistant mutants of M. tuberculosis. 183, 185, 186 No cross-resistance occurs between STR and either AMI or KAN, but crossresistance between AMI and KAN has been reported. 183, 185, 186 Recently, Taniguchi et al. 187 examined the molecular basis of resistance to KAN and VIO in M. smegmatis and identified an A->G change at position 1389 of 16S rRNA gene (rrs) in all laboratory-generated isolates resistant to high levels of KAN. In addition, mutations resulting in G->A or G->T changes at position 1473 of the M. smegmatis rrs gene were found in laboratory-generated VIO R organisms. The results of conjugation experiments showed that these mutations conferred resistance to KAN and VIO. 187 To determine if analogous mutations occurred in drugresistant M. tuberculosis patient isolates, 10 organisms Tuberculosis drug resistance update 17 variably resistant to STR, KAN, and VIO were analyzed for changes in rrs and rpsL genes. Importantly, three of four high-level KAN R mutants (MIC > 200 µg/ml) had the identical A->G change at position 1400 of rrs gene. 187 This nucleotide is equivalent to position 1389 in M. smegmatis and 1408 in E. coli, and mutations located at these nucleotides are known to confer KAN resistance.
188 One strain with high-level resistance to all three drugs (MIC > 200 µg/ml) lacked mutations at positions 1400 and 1483 (equivalent to position 1473 of M. smegmatis). This strain had an A->G change at position 705 of the rrs gene and also had an Lys43Arg substitution in RpsL. Although the Lys43Arg substitution is strongly associated with STR resistance, 13 it is unclear if the change at rrs located at position 705 is responsible for resistance to KAN and VIO. Finally, five strains with low level resistance to KAN and/or VIO (MIC < 50 µg/ml) lacked mutations in the rpsL and rrs genes, a result indicating that another molecular mechanism is operative in these organisms. Currently, no progress has been made in the understanding of the molecular basis of CAP R in M. tuberculosis. Building on these studies, Suzuki et al. 189 analyzed a 300-bp region of the rrs gene and the intervening sequence between the rrs gene and 23S rRNA gene in 43 KAN R and 71 KAN S strains from Japan. Nucleotide substitutions were identified in 29 of 43 (67%) KAN R strains at positions 1400, 1401, or 1483; 26 of the 29 organisms with mutations had an A->G substitution at position 1400. In contrast, all 71 KAN S organisms had the identical wild-type sequence in the region analyzed. Hence, these data suggest that nucleotide substitutions in the region of rrs analyzed are a major cause of resistance to kanamycin in M. tuberculosis.
Alangaden et al. 190 recently studied 14 human M. tuberculosis strains resistant to KAN and AMI and judged to be distinct by IS6110 subtyping. All isolates with high-level resistance (MIC > 32 µg/ml) to these antimicrobial agents had the same A->G mutation at position 1400 of rrs. In contrast, susceptible strains and organisms with low level resistance to KAN and AMI lacked this mutation. These data, taken together with the findings of Tanaguchi et al. 187 and Suzuki et al. 189 clearly implicate nucleotide substitutions at rrs position 1400 as important in high-level resistance to KAN and AMI. CYCLOSERINE D-cycloserine is a second-line anti-TB drug. This agent is a cyclic structural analog of D-alanine that inhibits cell wall synthesis. [191] [192] [193] Although an effective antimycobacterial agent, its use is limited by adverse side effects, including neurologic reactions. 194 The molecular genetic basis of resistance in M. tuberculosis is unknown, but a recent study provided potentially important insights.
Caceres et al. 195 found that the D-alanine racemase gene (alrA) from M. smegmatis was necessary and sufficient to confer cycloserine resistance to this organism. The Dalanine racemase activities of wild-type and recombinant M. smegmatis strains were inhibited by D-cycloserine in a concentration-dependent manner. Sequence analysis found that the D-cycloserine resistance phenotype in the recombinant clone was caused by overexpression of the wild-type alrA gene on a multicopy vector. Importantly, a spontaneous resistant mutant that overproduced AlrA had a single transversion (G->T) located in the alrA promoter. Transformation of M. bovis BCG with the M. smegmatis wild-type alrA gene in a multicopy vector conferred resistance to D-cycloserine. The investigators speculated that AlrA overproduction is a potential mechanism of D-cycloserine resistance in human isolates of M. tuberculosis. However, this idea remains to be formally tested.
MULTIDRUG-RESISTANT TUBERCULOSIS
MDR-TB strains are generally considered to be those resistant to at least INH and RIF. These strains have been described worldwide, and their existence poses a serious threat to TB control programs in many countries. The frequency of resistance to multiple drugs varies geographically, and acquired (secondary) resistance is more common than primary resistance. High rates of acquired MDR-TB have been reported in Nepal (48.0%); Gujarat, India (33.8%); and in New York City (~30%) early in this decade. 2, 210 Although recent studies have shown an overall decrease in number of MDR-TB cases reported in New York City 220 and the USA, 11 the number of states reporting these organisms actually increased substantially since the early 1990s. 210 Outbreaks of MDR-TB among patients with acquired immune deficiency syndrome have been associated with rapid progression, high mortality, and considerable cost to society. [209] [210] [211] 218 In addition, transmission of MDR-TB on a commercial airplane flight has been documented, 209 thereby contributing to the public concern about these strains. Notwithstanding some reports of limited success, 213, 217, 221 treatment of patients with MDR-TB is substantially more difficult than individuals infected with drug-sensitive strains.
In principle, MDR-TB strains could arise as a consequence of sequential accumulation of mutations conferring resistance to single therapeutic agents, or by a single-step process such as acquisition of an MDR element, or mutation that alters (for example) cell wall structure. All available evidence indicates that the former process is critical to the emergence of these organisms. Currently, there is no evidence that processes commonly mediating multidrug resistance in other bacteria, such as conjugal transfer of plasmids encoding combinations of resistance genes or transfer of transposable elements with resistance genes occur in M. tuberculosis.
A well-documented example of how multidrugresistant M. tuberculosis strains arise has been provided by the analysis of the evolution of two closely related subclones in New York City arbitrarily designated as strain W and W1 9 ( Fig. 9) . Together, these two related organisms have caused greater than 300 cases of tuberculosis in New York City and elsewhere. Automated DNA sequencing of representative organisms defined the exact series of distinct mutations conferring resistance to RIF, INH, STR, ETH, EMB, PZA, KAN, and FQs. 9, 154, 163, 174, 190 For example, a His526Tyr amino acid substitution was responsible for conferring RIF resistance and a Ser315Thr replacement was responsible for INH resistance. These drug-resistant strains have spread to other US cities and Europe. In addition, a recent study found that several patients had been infected with the W1 organism by a contaminated bronchoscope. 222 MDR-TB organisms also have been documented to be the cause of a nosocomial outbreak in Argentina. 223 Similarly, clonally-related strains of M. bovis resistant to INH, RIF, PZA, ETH, STR, AMI, CAP, para-aminosalicylic acid, clarithromycin, ethionamide, and ofloxacin caused 16 cases of tuberculosis in a nosocomial outbreak involving HIV-positive patients in Spain, 207, 224, 225 and transmission of this organism to an immunocompetent patient also has been documented. 226 These MDR isolates arise because random mutations in genes that encode targets for the individual antimicrobial agents are selected by subtherapeutic drug levels that can occur due to processes such as treatment errors, poor adherence to treatment protocols, or other factors. 25, 214, 216, 227 Given the considerable difficulties in successfully treating drug-resistant strains, 25, 227 the widespread dissemination of MDR-TB strains poses a serious threat to our global village. Several studies have documented that use of directly observed therapy is a critical factor in limiting the development of drug resistant strains. [228] [229] [230] Moreover, it is clear that new therapeutic agents or strategies are needed. Interestingly, the possibility that β-lactam drugs may be useful in the treatment of patients with MDR-TB is being investigated by several groups, although probably there will be a need to circumvent a β-lactamase made by many if not all isolates of M. tuberculosis.
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VIRULENCE AND DRUG RESISTANCE
One important question relating to the study of resistant M. tuberculosis is the relative virulence of drug-resistant and -susceptible strains. This issue has been controversial since publication several decades ago of a report that INH R strains lacking catalase activity had significantly reduced virulence for guinea pigs. 237 In addition, Subbaiah et al. 238 reported that a number of INH R M. tuberculosis strains isolated from patients in India tended to be of low catalase activity, an observation that may explain the low virulence in a guinea pig model of infection. Mouse studies employing a panel of 15 anti-TB agents, found that drug-resistant strains had a range of virulence. 239 No simple relationship was identified between degree of drug resistance and relative virulence, as defined by growth in lungs following aerogenic exposure to a low dose inoculum. Although these data are important, the exact molecular basis of drug resistance in these organisms was not defined. Hence, it was not possible to correlate relative virulence and specific drug resistance-conferring mutations.
A study conducted by Wilson et al. 240 provided strong evidence that KatG participates in virulence in a guinea pig model of M. bovis disease. Isogenic strains were used to demonstrate that KatG was essential for virulence, as assessed by ability to cause gross and microscopic pathology in spleen, liver, and lungs after subcutaneous injection. In contrast, no evidence was generated indicating that InhA directly participated in virulence in this model. The implication from this study is that INH R M. tuberculosis strains with significantly decreased KatG activity may be relatively less virulent for humans. Such a notion may explain the relative lack of INH R organisms with total katG deletions.
Recently Heym et al. 241 compared the virulence of isogenic mutants of M. tuberculosis which were either defective in KatG activity, or lacked KatG function but overproduced AhpC. The strains were tested in both normal and immunologically deficient mice. The virulence of the strains was studied in fully immunocompetent, MHC class II-knock out mice with abnormally low levels of CD4 T-cells, and athymic mice lacking a cellular immune response. The results indicated that M. tuberculosis strains producing catalase-peroxidase were considerably more virulent in immunocompetent mice than the isogenic katG deficient mutants. Restoration of virulence did not occur in the INH R M. tuberculosis strain that overexpressed AhpC, suggesting that AhpC is not a virulence factor in rodent infections.
Li et al. 242 have recently examined the role of catalaseperoxidase as a virulence factor for M. tuberculosis in mice and guinea pigs. The growth and persistence of drug susceptible M. tuberculosis strain H37Rv in BALB/c mice infected intravenously were compared with a katGdeleted (isoniazid-resistant) derivative of this bacterial strain. Transformation of the M. tuberculosis H37Rv, katG deleted strain with the katG gene obtained from the parent strain of this organism restored catalase-peroxidase activities and the ability of the recombinants to persist in spleens of guinea pigs and mice. Similarly, transformation of the katG-deleted H37Rv strain with the katG allele found in M. bovis and principal genetic group 1 M. tuberculosis isolates (KatG 463Leu) 85 also restored catalase-peroxidase activities and enhanced persistence. In contrast, transformants containing a mutant katG gene (Thr275Pro) expressed low levels of enzymatic activity, survived in mouse tissues, but failed to persist in guinea pig spleens. 242 The Thr275Pro KatG variant was used because it is associated with dramatic reduction in catalase-peroxidase activity and high-level resistance to INH. 87 Taken together, these important results add to the evidence that KatG is an M tuberculosis virulence factor.
RAPID DETECTION OF DRUG-RESISTANT STRAINS
Delineation of the molecular mechanisms of antimicrobial agent resistance has resulted in the development and application of several PCR-based strategies designed to rapidly detect mutations associated with resistance. These methods include direct sequencing of PCR products; SSCP analysis; heteroduplex analysis; dideoxy fingerprinting; an RNA/RNA duplex, base pair-mismatch assay; a luciferase mycobacteriophage strategy; a rRNA/ DNA-bioluminescence-labelled probe method; a reverse hybridization-based line probe assay; and other strategies. 13, [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] These methods are all designed to exploit the observation that specific polymorphisms found in resistant strains are absent in susceptible organisms. The fact that natural populations of drug-susceptible M. tuberculosis complex isolates recovered globally have remarkably few polymorphisms in structural genes greatly simplifies interpretation of these assay 15, 88, 262, 263 (Table 2 ). The restricted allelic variation in structural genes means that virtually all susceptible organisms will have the same wild-type allele of the target gene. Hence, one generally needs to differentiate between a single wild-type sequence and mutant sequences. This situation is in striking contrast to other bacteria in which many distinct naturally occurring alleles are usually found in the drug-susceptible condition. 88, [264] [265] [266] [267] In essence, the M. tuberculosis complex is an ideal situation for application of certain kinds of molecular diagnostic testing strategies.
Each molecular strategy has advantages and disadvantages, and a full discussion of this important topic is beyond the scope of this review. Among the many techniques used to identify drug resistance-associated mutations, automated DNA sequencing of PCR products has been the most widely applied. One important advantage of sequence-based approaches is that the resulting data are virtually unambiguous because the resistanceassociated mutation is either present or absent. Until recently, the considerable cost required to purchase a sequencing instrument was a major disadvantage. Automated sequencing has been used by several groups in routine clinical settings and been found to give excellent benefit to patient care activities. For example, Pai et al. 243 showed that rpoB data bearing on rifampin-resistance could be generated within a few days from growth obtained in an early BACTEC-positive culture. Similarly, Telenti's group demonstrated good performance of SSCPbased interrogation of target sequences. 128 In contrast, one group demonstrated that proper selection of oligonucleotide primer sequences is critical to the success of the SSCP approach. 78 The line-probe assay strategy has the advantages of relatively reliable performance, and potential commercial availability. All strategies suffer from the fact that for no antimycobacterial agent do we understand the molecular mechanism of resistance for 100% of organisms. Hence, identification of a resistanceassociated mutation is clinically informative whereas lack of a mutation in the target sequence must be interpreted with considerable caution. 
